

Muscarinic Acetylcholine Receptor M2 (CHRM2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/MF5B079DAC19EN.html>

Date: May 2022

Pages: 61

Price: US\$ 3,500.00 (Single User License)

ID: MF5B079DAC19EN

Abstracts

Muscarinic Acetylcholine Receptor M2 (CHRM2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Muscarinic Acetylcholine Receptor M2 (CHRM2) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. The latest report Muscarinic Acetylcholine Receptor M2 - Drugs In Development, 2022, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Muscarinic cholinergic receptor 2 is an acetylcholine receptor. It is expressed in various regions of the brain including the cerebellum, cerebral cortex, hippocampus, medulla, striatum, and thalamus, and in lung and prostate. It mediates smooth muscle contractility. Increase in M2 receptor has been associated with depression. The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 1, 2, 5 and 2 respectively.

Report covers products from therapy areas Central Nervous System, Respiratory,

Genito Urinary System And Sex Hormones, Cardiovascular, Dermatology, Genetic Disorders and Undisclosed which include indications Alzheimer's Disease, Obstructive Sleep Apnea, Overactive Bladder, Parkinson's Disease, Angelman Syndrome, Axillary Hyperhidrosis, Depression, Fragile X Syndrome, Infantile Spasm (West Syndrome), Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Psychosis, Rett Syndrome, Schizophrenia, Snoring, Stroke, Tuberos Sclerosis, Unspecified Rare Disease and Urinary Incontinence.

Furthermore, this report also reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M2 (CHRM2)

The report reviews Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics and enlists all their major and minor projects

The report assesses Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted

therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M2 (CHRM2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M2 (CHRM2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Overview

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Companies Involved in Therapeutics Development

Anavex Life Sciences Corp

Apnimed Inc

Dermavant Sciences Inc

Karuna Therapeutics Inc

Sinsin Pharmaceutical Co Ltd

TheraVida Inc

Trigone Pharma Ltd

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Drug Profiles

(atomoxetine + oxybutynin) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(lidocaine + oxybutynin) SR - Drug Profile

Product Description

Mechanism Of Action

History of Events

(oxybutynin + pilocarpine) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(oxybutynin + reboxetine) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(pilocarpine + tolterodine) - Drug Profile

Product Description

Mechanism Of Action

History of Events

(trospium chloride + xanomeline) - Drug Profile

Product Description

Mechanism Of Action

History of Events

AD-109 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ANAVEX-141 - Drug Profile

Product Description

Mechanism Of Action

History of Events

blarcamesine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

oxybutynin - Drug Profile

Product Description

Mechanism Of Action

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Dormant Products

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Discontinued Products

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Product Development Milestones

Featured News & Press Releases

May 18, 2022: Karuna Therapeutics to host virtual event highlighting clinical program for psychosis in Alzheimer's disease

Mar 15, 2022: Anavex Life Sciences announces presentation of phase 2 clinical biomarker data from Anavex 2-73-PDD-001 Parkinson's disease dementia study at AD/PD™ 2022 International Conference

Mar 09, 2022: Apnimed study APC-004 phase 2 data to be presented at World Sleep 2022

Feb 04, 2022: Anavex life sciences provides supplemental information on ANAVEX 2-73 (blarcamesine) AVATAR Phase 3 trial for the treatment of adult patients with Rett syndrome

Feb 01, 2022: ANAVEX 2-73 (Blarcamesine) AVATAR phase 3 trial met primary and

secondary efficacy endpoints

Dec 16, 2021: Apnimed announces dosing of first patient in phase 3 MARIPOSA confirmatory trial of AD504, a potential nighttime oral treatment for Obstructive Sleep Apnea (OSA)

Oct 13, 2021: Anavex Life Sciences reports data review by the independent DSMB reported for phase 2b/3 trial of ANAVEX 2-73 for AD

Oct 13, 2021: Apnimed announces positive phase 2 (Study APC-003) data demonstrating durability-of-effect and improved quality-of-life in patients with obstructive sleep apnea after investigational AD109 treatment

Oct 13, 2021: Apnimed announces positive phase 2 data (Study APC-004) demonstrating improvement in measures of obstructive sleep apnea and a dose-response with AD109, an oral pharmacologic investigational treatment for the disease

Sep 13, 2021: Novamind to serve as research site for Karuna Therapeutics late-stage clinical trial

Aug 26, 2021: Anavex Life Sciences announces publication of Foundational data for ANAVEX2-73 (blarcamesine) in Fragile X syndrome (Autism)

Aug 13, 2021: Trigone Pharma announces the initiation of a phase 2 clinical trial of TRG-100 in patients with interstitial cystitis/bladder pain syndrome

Jul 29, 2021: Anavex Life Sciences announces ANAVEX2-73 (Blarcamesine) significantly prevented A β (Abeta)-induced cognitive deficits with Confirmed Significant Biomarker-response in Animal Model of Alzheimer's Disease

Jul 22, 2021: Trigone Pharma to present preclinical data for TRG-100 in interstitial cystitis / bladder pain syndrome at the upcoming American Urological Association Conference (AUA) in September 2021

Jun 29, 2021: Anavex reports positive data from Parkinson's disease dementia study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Anavex Life Sciences Corp, 2022

Pipeline by Apnimed Inc, 2022

Pipeline by Dermavant Sciences Inc, 2022

Pipeline by Karuna Therapeutics Inc, 2022

Pipeline by Sinsin Pharmaceutical Co Ltd, 2022

Pipeline by TheraVida Inc, 2022

Pipeline by Trigone Pharma Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

I would like to order

Product name: Muscarinic Acetylcholine Receptor M2 (CHRM2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/MF5B079DAC19EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MF5B079DAC19EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

